



GLOBAL ACTION PLAN 2 GLOBAL PROSTATE CANCER  
IMAGING INITIATIVE

## GAP2 INFO SHEET

### WHAT'S IT ALL ABOUT?

Developing new tracers and techniques, which will enable better and earlier detection of prostate cancer spread.

The three tracers currently under investigation are:

#### 01

Fluorodihydrotestosterone (FDHT) - a project with contributions from research groups in Australia, the Netherlands, UK and USA.

#### 02

Fluoro-methyl-choline (FCH) - a project with contributions from research groups in Australia, Canada and UK

#### 03

Prostate Specific Membrane Antigen (PSMA) - a joint research project with researchers from Canada and USA.

### BUT WHAT DOES IT ALL MEAN?

Specifically, we are looking at improving the treatment options for men who have advanced disease where cancer has spread outside the prostate. If these trials prove successful, the treating physicians will have a clearer picture about what the best treatment might be for a specific individual:

- The FDHT trial will test a new tracer that has been designed to be able to tell specifically what types of cells exist in a particular cancer deposit.
- The Choline and PSMA projects are looking at men who have had their prostate removed, but who are showing early signs that the cancer may be coming back. If these trials work, the current level at which we can see metastasis (cancer spread) could potentially be brought forward by weeks or months.

### WHO'S INVOLVED?

18 researchers from  
17 institutions across  
5 countries:



APPROX. AUD  
**5 MILLION**  
COMMITTED  
TO DATE

### WHAT'S TO COME?

The FDHT and choline trials are anticipated to recruit men throughout the 2015 calendar year. The researchers believe that the work will lead to a meaningful clinical impact within the next 5 years so that these tests can be used as part of routine clinical care in the near future.

### HOW WILL THIS HELP MEN?

This project will ultimately impact men with advanced prostate cancer. This includes men who have a rising PSA level after surgery to remove their prostate gland and also men who have widespread, castrate-resistant cancer. These men may have better outcomes if treatments can be more appropriately directed by new imaging tests.

### WHAT'S HAPPENING NOW?

- The GAP2 FDHT project will aim to recruit 105 men with widespread prostate cancer in 4 international centres. This trial has commenced recruitment and will continue to recruit men throughout 2015.
- The GAP2 Choline project aims to recruit 140 men to the trial and recruitment has commenced in. It is expected that recruitment for this project will also be completed throughout 2015.
- Initial work for the PSMA project in Canada is on track to be completed by mid-2015 and then the team will embark on a small clinical trial on 20 men, to prove that it works.

FIND OUT MORE ON THE  
[REPORT CARD](#)

PAUL VILLANTI, EXECUTIVE DIRECTOR, SAYS: "THE GAP2 PROJECT AIMS TO CREATE NEW AND NOVEL TRACERS FOR MEN WITH ADVANCED DISEASE. THESE TRACERS HAVE THE POTENTIAL TO ALLOW FOR BETTER TREATMENT DECISIONS AND ULTIMATELY IMPROVE THE OUTCOMES FOR MEN WHOSE DISEASE GROWS OUTSIDE THE PROSTATE. THIS IS CRITICAL TO REDUCING THE SUFFERING THAT PROSTATE CANCER INFLICTS ON MEN"